n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with paclitaxel in 1 studies
| Studies (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Trials (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Recent Studies (post-2010) (n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
|---|---|---|---|---|---|
| 18 | 5 | 13 | 31,874 | 5,729 | 15,395 |
| Protein | Taxonomy | n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide (IC50) | paclitaxel (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.034 | |
| Integrin alpha-V | Homo sapiens (human) | 0.034 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.598 | |
| Botulinum neurotoxin type A | Clostridium botulinum | 5.2 | |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | 4.9 | |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | 4.9 | |
| Substance-K receptor | Homo sapiens (human) | 6.125 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 4.9 | |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | 4.9 | |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | 4.9 | |
| Delta-type opioid receptor | Homo sapiens (human) | 4.202 | |
| Tyrosine-protein kinase Mer | Homo sapiens (human) | 4.9 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 0.0082 | |
| Beta-tubulin | Leishmania donovani | 1 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 7.9433 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 0.26 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.28 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, D; Meng, G; Zheng, W | 1 |
1 other study(ies) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and paclitaxel
| Article | Year |
|---|---|
Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Indoles; Integrin alpha2beta1; Mice; Mice, Nude; Microtubules; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |